UNSPSC 51352433: Estrogens/iron/methamphetamine/methyltestosterone/multivitamins

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.

UNSPSC 51352433 Estrogens/iron/methamphetamine/methyltestosterone/multivitamins is a Commodity code covering branded and generic pharmaceutical products in these therapeutic classes, as demonstrated by state and local procurement activity focused on generic multi-source pharmaceuticals, over-the-counter (OTC) products, and direct-to-manufacturer prescription programs. State health and human services agencies and cooperative purchasing alliances are the primary soliciting bodies under this code, reflecting a shift toward managing pharmacy benefit costs through direct manufacturer relationships and consolidated purchasing arrangements that bypass traditional pharmacy benefit managers and group purchasing organizations. The scope of work centers on supplying medications with specific National Drug Codes (NDC), maintaining regulatory compliance including cGMP and Drug Supply Chain Security Act (DSCSA) certification, and establishing tiered pricing models (flat price, net price formats, WAC-minus) that accommodate government and self-insured employer health plans.

Recent activity spans multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; awarded vendors will be effective July 1, 2026 and serve participating state and local government facilities including Oregon. The Texas Health and Human Services Commission posted a Request for Information (RFI) on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program, signaling movement toward restructured procurement models that emphasize direct contracting with manufacturers over traditional wholesale channels. Both solicitations emphasize pricing competitiveness (weighted at 75 percent in MMCAP's evaluation) and regulatory compliance, with MMCAP requiring vendors to maintain relationships with at least two of three authorized wholesalers and commercial general liability insurance of $5,000,000 per occurrence.